BriaCell Therapeutics Corp. (BCTX)
NASDAQ
Closed
Oct 8, 2026
Day's Range
3.8752 wk Range
2.60Overview - BCTX - BriaCell Therapeutics Corp.
Key Statistics
Valuation
Enterprise Value
11.69M
P/E (Trailing)
‪-0.06‬
P/E (Forward)
‪-10.35‬
PEG Ratio
‪0.00067‬
Price / Book
‪1.21‬
EV / EBITDA
‪-0.36‬
Profitability
Profit Margin
‪0.00%‬
Operating Margin
‪0.00%‬
Return on Assets
‪-90.84%‬
Return on Equity
‪-175.25%‬
Ownership
Shares Outstanding
7.25M
Float
7.85M
Short % of Shares Outstanding
‪9.11%‬
Held by Insiders
‪0.04%‬
Held by Institutions
‪6.39%‬
Price stats
Beta
‪1.53‬
50-Day Avg
‪3.72‬
200-Day Avg
‪4.24‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
1 analysts
Shariah Compliance
Report Date: Feb 18, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - BCTX - BriaCell Therapeutics Corp.
Peers - BCTX - BriaCell Therapeutics Corp.
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- BCTXNASDAQBriaCell Therapeutics Corp.35.14MMarket Cap-227.23%52-week change-0.06P/E (Trailing)‪0.00%‬Profit Margin
- ARGXNASDAQArgenx SE57.50BMarket Cap+14.28%52-week change34.96P/E (Trailing)‪32.26%‬Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals, Inc.29.40BMarket Cap-105.72%52-week change38.35P/E (Trailing)‪16.12%‬Profit Margin
- BNTXNASDAQBioNTech SE American Depositary Share24.34BMarket Cap-8.52%52-week change160.80P/E (Trailing)‪-63.63%‬Profit Margin
- ASNDNASDAQAscendis Pharma A/S14.99BMarket Cap+7.48%52-week change17.72P/E (Trailing)‪70.84%‬Profit Margin
- BBIONASDAQBridgeBio Pharma Inc.13.14BMarket Cap+18.80%52-week change-17.80P/E (Trailing)‪-97.02%‬Profit Margin
- BMRNNASDAQBioMarin Pharmaceutical Inc.11.06BMarket Cap+2.75%52-week change154.54P/E (Trailing)‪2.14%‬Profit Margin
Profile Summary - BCTX - BriaCell Therapeutics Corp.
About
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer. BriaCell Therapeutics Corp. is best known for its cell-based oncology programs, including Bria-IMT, a lead therapy being studied for metastatic breast cancer, along with Bria-OTS, a…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
